TNXP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tonix Pharmaceuticals Holding Corp (TNXP) is not a strong buy at this moment for a beginner investor with a long-term strategy. Despite insider buying and revenue growth, the company's financial performance remains weak with significant net losses and declining EPS. Additionally, technical indicators and options data do not suggest a strong upward momentum. It is better to hold off on investing in TNXP until clearer positive catalysts emerge.
The MACD is positive but contracting, RSI is neutral at 38.433, and moving averages are converging, indicating no strong trend. The stock is trading near its key support level of 13.497, with resistance levels at 16.416 and 17.317. Pre-market price is down 1.38%, showing weak momentum.
Insiders are buying significantly, with a 1382.97% increase in the last month. Revenue increased by 108.75% YoY in Q4 2025, and gross margin improved to 80.37%.
No recent news or major events to drive the stock. Net income remains deeply negative at -46.91M, and EPS dropped significantly by -59.67% YoY. Pre-market price is down 1.38%, and SP500 is also down 0.45%, indicating weak market sentiment.
In Q4 2025, revenue grew by 108.75% YoY to 5.39M, but net income remains negative at -46.91M, up 112.19% YoY. EPS dropped to -3.96, down -59.67% YoY. Gross margin increased to 80.37%, up 48.34% YoY, showing some operational improvement but not enough to offset losses.
No recent analyst ratings or price target changes available.
